NEW YORK (360Dx) – Mologic said today that it has signed European distribution agreements for its Periplex point-of-care test for detection of infections in patients undergoing peritoneal dialysis.
The Periplex test detects two biomarkers of infection — interleukin 6 and matrix metalloproteinase-8 — in peritoneal dialysis waste fluid using a lateral flow immunoassay system, and provides results within 10 minutes. It received CE marking about a year ago.
According to Mologic, the test will now be distributed by Aix-en-Provence, France-based Medisur and Zurich-based Peripal in France, Germany, Italy, The Netherlands, Austria, and Switzerland. Specific terms of the deals were not disclosed.
"Establishing a global distribution network is integral to Mologic's product commercialization strategy," Mologic Cofounder and CEO Mark Davis said in a statement. "With the appointment of distributors across Europe, we will ensure Periplex is available to more patients, giving them greater choice and the confidence to monitor their dialysis at home."